Compare AJANTA PHARMA with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN AJANTA PHARMA/
LUPIN
 
P/E (TTM) x 22.3 -19.1 - View Chart
P/BV x 5.3 2.1 250.9% View Chart
Dividend Yield % 0.8 1.0 74.6%  

Financials

 AJANTA PHARMA   LUPIN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-21
LUPIN
Mar-21
AJANTA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,8831,122 167.8%   
Low Rs1,258576 218.5%   
Sales per share (Unadj.) Rs334.0334.2 99.9%  
Earnings per share (Unadj.) Rs75.627.0 279.5%  
Cash flow per share (Unadj.) Rs89.046.6 191.0%  
Dividends per share (Unadj.) Rs9.506.50 146.2%  
Avg Dividend yield %0.60.8 79.0%  
Book value per share (Unadj.) Rs346.1300.1 115.4%  
Shares outstanding (eoy) m86.53453.68 19.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x4.72.5 185.2%   
Avg P/E ratio x20.831.4 66.2%  
P/CF ratio (eoy) x17.718.2 96.9%  
Price / Book Value ratio x4.52.8 160.4%  
Dividend payout %12.624.0 52.3%   
Avg Mkt Cap Rs m135,898385,072 35.3%   
No. of employees `000NANA-   
Total wages/salary Rs m5,48328,259 19.4%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m28,897151,630 19.1%  
Other income Rs m2601,363 19.1%   
Total revenues Rs m29,157152,993 19.1%   
Gross profit Rs m9,98625,669 38.9%  
Depreciation Rs m1,1618,874 13.1%   
Interest Rs m831,406 5.9%   
Profit before tax Rs m9,00216,751 53.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4634,485 54.9%   
Profit after tax Rs m6,53912,266 53.3%  
Gross profit margin %34.616.9 204.1%  
Effective tax rate %27.426.8 102.2%   
Net profit margin %22.68.1 279.7%  
BALANCE SHEET DATA
Current assets Rs m22,178139,864 15.9%   
Current liabilities Rs m8,38884,361 9.9%   
Net working cap to sales %47.736.6 130.4%  
Current ratio x2.61.7 159.5%  
Inventory Days Days5369 76.3%  
Debtors Days Days9108 8.7%  
Net fixed assets Rs m18,91294,439 20.0%   
Share capital Rs m174907 19.2%   
"Free" reserves Rs m29,777135,229 22.0%   
Net worth Rs m29,951136,136 22.0%   
Long term debt Rs m16161 9.9%   
Total assets Rs m41,090234,302 17.5%  
Interest coverage x109.812.9 850.8%   
Debt to equity ratio x00 45.1%  
Sales to assets ratio x0.70.6 108.7%   
Return on assets %16.15.8 276.2%  
Return on equity %21.89.0 242.3%  
Return on capital %30.313.3 227.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m18,09751,027 35.5%   
Fx outflow Rs m2,31521,081 11.0%   
Net fx Rs m15,78229,946 52.7%   
CASH FLOW
From Operations Rs m5,76318,218 31.6%  
From Investments Rs m-2,824-12,396 22.8%  
From Financial Activity Rs m-3,183-18,853 16.9%  
Net Cashflow Rs m-244-13,031 1.9%  

Share Holding

Indian Promoters % 70.5 46.5 151.6%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 21.4 41.9 51.1%  
FIIs % 8.6 14.7 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.5 53.2 55.5%  
Shareholders   60,759 378,547 16.1%  
Pledged promoter(s) holding % 16.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    

Yellow Ad

Advertisement

How to Find One Stock with Crorepati Potential?

There are three critical characteristics that differentiate a common stock from a potential 'crorepati' stock.

And we are going to reveal them during our 'One Stock Crorepati' MEGA summit on 30th June.

If you are interested in finding a potential 'crorepati' stock, don't miss this.

At this MEGA Summit we will reveal details of what we call a 'crorepati' stock...

You just cannot afford to miss this summit for anything.

Learn more



Today's Market

Sensex, Nifty Rebound from Day's Low to End Flat; IT & Auto Stocks Witness Buying(Closing)

Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 28, 2022 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS